Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Rimexolone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 9/20 | 0.88 |
| ▸ | PGR | P06401 | 7/20 | 0.88 |
| ▸ | HIF1A | Q16665 | 6/20 | 0.88 |
| ▸ | LMNA | P02545 | 3/20 | 0.88 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.88 |
| ▸ | CNR1 | P21554 | 1/20 | 0.88 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.55 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.55 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.55 |
| ▸ | AR | P10275 | 2/20 | 0.55 |
| ▸ | TNF | P01375 | 1/20 | 0.55 |
| ▸ | IL6 | P05231 | 1/20 | 0.55 |
| ▸ | SERPINA6 | P08185 | 1/20 | 0.55 |
| ▸ | GLUL | P15104 | 1/20 | 0.55 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.55 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.53 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rimexolone SCHEMBL445300 | 0.94 | NR3C1 (1.00) | NR3C1PGRHIF1ALMNANR1I2 | |
| Rimexolone SCHEMBL1651214 | 0.94 | NR3C1 (1.00) | NR3C1PGRHIF1ALMNANR1I2 | |
| Rimexolone SCHEMBL29030109 | 0.94 | NR3C1 (1.00) | NR3C1PGRHIF1ALMNANR1I2 | |
| Rimexolone SCHEMBL29030108 | 0.94 | NR3C1 (1.00) | NR3C1PGRHIF1ALMNANR1I2 | |
| Rimexolone SCHEMBL13693339 | 0.94 | NR3C1 (1.00) | NR3C1PGRHIF1ALMNANR1I2 | |
| SCHEMBL4149 | 0.94 | NR3C1 (0.76) | NR3C1PGRHIF1ALMNANR1I2 | |
| Rimexolone SCHEMBL3062722 | 0.94 | NR3C1 (1.00) | NR3C1PGRHIF1ALMNANR1I2 | |
| SCHEMBL9470890 | 0.87 | NR3C1 (0.86) | NR3C1PGRHIF1ALMNANR1I2 | |
| SCHEMBL9470879 | 0.87 | NR3C1 (0.86) | NR3C1PGRHIF1ALMNANR1I2 | |
| SCHEMBL13524476 | 0.86 | NR3C1 (0.78) | NR3C1PGRHIF1ALMNANR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240226116-A1 | Glucocorticoid Particles and Their Use | CRITITECH, INC. | 2024-07-11 | — | — | US | disclosed |
| EP-3426285-B1 | FORMULATIONS AND DOSES OF PEGYLATED URICASE | CARTESIAN THERAPEUTICS INC (US) | 2024-05-29 | — | — | EP | disclosed |
| US-20240100068-A1 | METHODS COMPRISING ADMINISTRATION OF A GLUCOCORTICOID RECEPTOR AGONIST AND AN INHIBITOR OF CALCINEURIN | CHENGDU ANTICANCER BIOSCIENCE LTD (CN) | 2024-03-28 | — | — | US | disclosed |
| US-11931368-B2 | Glucocorticoid “nintedanib” particles and their use | CRITITECH, INC. (US) | 2024-03-19 | — | — | US | disclosed |
| EP-4281051-A1 | VESICLES AND USES THEREOF | Exocure Sweden AB (SE) | 2023-11-29 | — | — | EP | disclosed |
| US-20230119226-A1 | METHODS AND COMPOSITIONS RELATED TO COMBINED TREATMENT WITH ANTI-INFLAMMATORIES AND SYNTHETIC NANOCARRIERS COMPRISING AN IMMUNOSUPPRESSANT | SELECTA BIOSCIENCES, INC. (US) | 2023-04-20 | — | — | US | disclosed |
| EP-3980784-A1 | FORMULATIONS AND DOSES OF PEGYLATED URICASE | Selecta Biosciences, Inc. (US) | 2022-04-13 | — | — | EP | disclosed |
| US-20210187081-A1 | FORMULATIONS AND DOSES OF PEGYLATED URICASE | SELECTA BIOSCIENCES, INC. (US) | 2021-06-24 | — | — | US | disclosed |
| US-20200390718-A1 | METHODS AND COMPOSITIONS FOR ATTENUATED ANTI-VIRAL TRANSFER VECTOR IMMUNE RESPONSE | SELECTA BIOSCIENCES, INC. (US) | 2020-12-17 | — | — | US | disclosed |
| WO-2020247625-A1 | FORMULATIONS AND DOSES OF PEGYLATED URICASE | SELECTA BIOSCIENCES, INC. (GB) | 2020-12-10 | — | — | WO | disclosed |
| WO-2020243261-A1 | METHODS AND COMPOSITIONS FOR ATTENUATED ANTI-VIRAL TRANSFER VECTOR IMMUNE RESPONSE | SELECTA BIOSCIENCES, INC. (US) | 2020-12-03 | — | — | WO | disclosed |
| US-20200246355-A1 | Glucocorticoid Particles and Their Use | CRITITECH, INC. | 2020-08-06 | — | — | US | disclosed |
| US-20180289776-A1 | METHODS AND COMPOSITIONS RELATED TO COMBINED TREATMENT WITH ANTIINFLAMMATORIES AND SYNTHETIC NANOCARRIERS COMPRISING AN IMMUNOSUPPRESSANT | SELECTA BIOSCIENCES, INC. | 2018-10-11 | — | — | US | disclosed |
| US-20170258927-A1 | FORMULATIONS AND DOSES OF PEGYLATED URICASE | SELECTA BIOSCIENCES, INC. | 2017-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240100068-A1 | METHODS COMPRISING ADMINISTRATION OF A GLUCOCORTICOID RECEPTOR AGONIST AND AN INHIBITOR OF CALCINEURIN | PPP3R1, CHP1, NR3C1 | NR3C1 3/4885PGR 402/4885HIF1A 4422/4885 |
| US-20200390718-A1 | METHODS AND COMPOSITIONS FOR ATTENUATED ANTI-VIRAL TRANSFER VECTOR IMMUNE RESPONSE | HAVCR2, CCL5, IRF3 | NR3C1 30/4885PGR 1498/4885HIF1A 3484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.